Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Free Cash Flow (2022 - 2025)

Historic Free Cash Flow for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Q3 2025 value amounting to -$5.8 million.

  • Day One Biopharmaceuticals' Free Cash Flow fell 10552.84% to -$5.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$139.2 million, marking a year-over-year decrease of 5424.84%. This contributed to the annual value of -$98.1 million for FY2024, which is 3329.14% up from last year.
  • Per Day One Biopharmaceuticals' latest filing, its Free Cash Flow stood at -$5.8 million for Q3 2025, which was down 10552.84% from -$23.1 million recorded in Q2 2025.
  • Day One Biopharmaceuticals' Free Cash Flow's 5-year high stood at $105.0 million during Q3 2024, with a 5-year trough of -$104.1 million in Q2 2024.
  • Over the past 4 years, Day One Biopharmaceuticals' median Free Cash Flow value was -$35.3 million (recorded in 2022), while the average stood at -$29.7 million.
  • The largest annual percentage gain for Day One Biopharmaceuticals' Free Cash Flow in the last 5 years was 38298.88% (2024), contrasted with its biggest fall of 14454.33% (2024).
  • Day One Biopharmaceuticals' Free Cash Flow (Quarter) stood at -$35.3 million in 2022, then decreased by 17.19% to -$41.4 million in 2023, then decreased by 19.04% to -$49.3 million in 2024, then skyrocketed by 88.22% to -$5.8 million in 2025.
  • Its last three reported values are -$5.8 million in Q3 2025, -$23.1 million for Q2 2025, and -$61.0 million during Q1 2025.